Ibrutinib CAS 936563-96-1 Puritas >99.5% (HPLC) API

Description:

Chemical Name: Ibrutinib

CAS: 936563-96-1

Puritas: >99.5% (HPLC)

Aspectus: Alba ad Off-White Crystal pulveris

Ibrutinib est inhibitor BTK tractaturus Chronica Lymphocytica Leukemia (CLL) et Mantle Cell Lymphoma (MCL)

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum	Ibrutinib
Synonyma	1-[(3R) -3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- unus;PCI-32765
CAS Number	936563-96-1
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C25H24N6O2
M. Pondus	440.50
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	White ad Off-Crystal pulveris
Lepidium sativum	IR;HPLC
Damnum in Siccatio	<0.50%
Residere in Ignition	≤0.10%
Metalla gravia (ut Pb)	≤20ppm
Unam immunditiam	≤0.20%
Totalis immunditias	<0.50%
Puritas / Analysis Methodus	>99.5% (HPLC)
Test Standard	Enterprise Standard
Consuetudinem	API

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

Ibrutinib (CAS: 936563-96-1) est inhibitor tyrosini kinasi Brutonis (BTK) ad curationem lymphocytici longi (CLL) et pallium cellae lymphomae (MCL).Tam MCL quam CLL pertinent ad lymphoma B-cell non Hodgkin, quod est refractarium et pronum ad relapsus.Communis usus chemoimmunotherapy non iaculis est, et gradus 3 vel 4 adversae motus saepe occurrunt.Ibrutinib coniungi potest cum BTK, quae necessaria est ad formationem, differentiam, communicationem et salutem lymphocytorum B, et irrevocabiliter actionem BTK inhibere, efficaciter inhibere proliferation et superstes cellularum tumoris.Praeterea, post administrationem oris celeriter absorbetur, maxima concentratio plasma 1~2h pervenit, et adversae reactiones sunt gradus 1 vel 2, quae nova optio fiet pro curatione CLL et MCL.Die XIII mensis Novembris anno MMXIII, US FDA accelerare probatus Johnson & Johnson societatem Imbruvicam et Civitates Americae Unitas (nomen commune Ibrutinib) ad tractandum lymphoma cellae manticae (MCL).Ibrutinib, concessum est status breakthrough Therapy a FDA in Februario 2013 et probatus est pro MCL die 13 Novembris, 2013 et CLL in die 12 Februarii 2014, respective.